drugset / Trial / NCT03129256
An Exploration of Apatinib Combined With S-1 in Patients With Advanced Non-small Cell Lung Cancer
NaSingle-groupOpen-labelTreatment
Summary
This study is to explore the potential efficacy and safety of low-dose Apatinib combined with S-1 in patients with advanced lung cancer. Patients with advanced NSCLC will be treated with oral apatinib and S-1 after treatment failure of standard regimen.
Timeline
- Start
- 2016-12-01
- Primary completion
- 2018-12-30
- Completion
- 2018-12-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Rivoceranib | Small molecule | 250 mg | Oral |
| Subject | S-1 | Small molecule | 40 mg | Oral |
| Subject | S-1 | Small molecule | 60 mg | Oral |